Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3102903 | 1.00 | TRPV1 (0.58) | TRPV1SCN10A | |
| SCHEMBL14302773 | 0.89 | TRPV1 (0.61) | TRPV1 | |
| SCHEMBL3103219 | 0.85 | TRPV1 (0.59) | TRPV1SCN10A | |
| SCHEMBL3103201 | 0.85 | TRPV1 (0.59) | TRPV1SCN10A | |
| SCHEMBL3781162 | 0.84 | TRPV1 (0.58) | TRPV1SCN10A | |
| SCHEMBL3781161 | 0.84 | TRPV1 (0.58) | TRPV1SCN10A | |
| SCHEMBL3096135 | 0.79 | TRPV1 (0.52) | TRPV1 | |
| SCHEMBL3096143 | 0.79 | TRPV1 (0.52) | TRPV1 | |
| SCHEMBL19078522 | 0.78 | TRPV1 (0.43) | TRPV1 | |
| SCHEMBL3784933 | 0.78 | TRPV1 (0.50) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318768-B2 | Bronchodilating alpha, beta-unsaturated isoquinoline amides | RESPIRATORIUS AB (SE) | 2012-11-27 | — | — | US | disclosed |
| US-8318768-B2 | Bronchodilating alpha, beta-unsaturated isoquinoline amides | RESPIRATORIUS AB (SE) | 2012-11-27 | — | — | US | disclosed |
| US-8318768-B2 | Bronchodilating alpha, beta-unsaturated isoquinoline amides | RESPIRATORIUS AB (SE) | 2012-11-27 | — | — | US | disclosed |
| EP-2181095-B1 | NOVEL BRONCHODILATING ALPHA, BETA-UNSATURATED ISOQUINOLINE AMIDES | RESPIRATORIUS AB (SE) | 2012-08-22 | — | — | EP | disclosed |
| US-20100256101-A1 | NOVEL BRONCHODILATING ALPHA, BETA-UNSATURATED ISOQUINOLINE AMIDES | ARCEDE PHARMA AB (SE) | 2010-10-07 | — | — | US | disclosed |
| US-20100256101-A1 | NOVEL BRONCHODILATING ALPHA, BETA-UNSATURATED ISOQUINOLINE AMIDES | ARCEDE PHARMA AB (SE) | 2010-10-07 | — | — | US | disclosed |
| US-20100256101-A1 | NOVEL BRONCHODILATING ALPHA, BETA-UNSATURATED ISOQUINOLINE AMIDES | ARCEDE PHARMA AB (SE) | 2010-10-07 | — | — | US | disclosed |
| WO-2009007420-A1 | NOVEL BRONCHODILATING ALPHA, BETA-UNSATURATED ISOQUINOLINE AMIDES | RESPIRATORIUS AB (SE) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256101-A1 | NOVEL BRONCHODILATING ALPHA, BETA-UNSATURATED ISOQUINOLINE AMIDES | PTGIS, ADRB2, ADRB1 | TRPV1 537/4885SCN10A 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.